A new study published in BIO Integration has identified distinct metabolic differences in the blood of individuals with latent tuberculosis infection (LTBI), revealing a panel of four metabolites capable of distinguishing LTBI from uninfected individuals with near-perfect accuracy.
Metabolic Fingerprint of Latent TB
The research examined plasma samples from two groups: 100 individuals who tested positive for LTBI (via QuantiFERON-TB Gold) and were recruited from close contacts of TB patients, and 99 non-infected individuals (QuantiFERON-TB Gold-negative) recruited from prison detainees.
Using ultra-high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry, researchers identified 43 metabolites that showed significant differences between the two groups.
Top Biomarkers Show Exceptional Performance
Four specific metabolites demonstrated high discriminatory ability, with area under the curve (AUC) values ranging from 0.975 to 0.981:
- Leucylleucine
- Tryptophyl-phenylalanine
- LysoPE(18:1(11Z)/0:0)
- Biliverdin
Models combining selected metabolites achieved even higher apparent classification performance under internal validation, with some AUC values approaching 1.00.
Crucial Limitations Noted
The study authors emphasize several important caveats that warrant caution:
"The two groups came from different source populations, potentially introducing selection bias."
Additional limitations include:
- Metabolites were identified at Metabolomics Standards Initiative level 2, without confirmation via authentic standards
- No external validation was performed on an independent cohort
Path to Clinical Application
The authors conclude that before this approach can be considered for clinical interpretation, further validation is required. Independent validation in well-matched cohorts using targeted metabolomic approaches remains necessary.
This research highlights a promising, non-invasive avenue for LTBI diagnosis through metabolic profiling, though the path from discovery to clinical application still requires rigorous, well-controlled studies.